<DOC>
	<DOCNO>NCT00632034</DOCNO>
	<brief_summary>The aim trial determine safety tolerability expand autologous progeny adult CD34+ ( haemopoietic ) stem cell subset infuse directly tibial artery patient recent tibial fracture . The trial also seek determine clinical improvement deterioration measurement clinical parameter , length time union fracture , change bone mineral density , improvement pain score ( VAS ) , functional ability ( TUGT ) IPAQ score .</brief_summary>
	<brief_title>Stem Cells Tibial Fractures</brief_title>
	<detailed_description />
	<mesh_term>Fractures , Bone</mesh_term>
	<mesh_term>Tibial Fractures</mesh_term>
	<criteria>Confirmed close tibial fracture one limb Normal blood count Normal coagulation screen Life expectancy least 12 month Ability give write informed consent Patients additional low limb injury Patients abnormal low limb vasculature Pregnant lactate woman Unexplained abnormal baseline laboratory result Males females capable reproduction take acceptable measure prevent reproduction study Subjects test positive HTLV , HIV , hepatitis B hepatitis C , chronic inflammatory disease , autoimmune disease chronic immunosuppressive medication History alcohol drug abuse within 3 month screen Subjects evidence ( clinical , laboratory , image ) cancer cancer recurrence within past 5 year ( nonmelanoma skin cancer situ cervical carcinoma ) Currently enrol another investigational device drug trial complete required followup period Patients unable give write informed consent</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>fracture</keyword>
	<keyword>tibia</keyword>
	<keyword>stem cell</keyword>
</DOC>